novo-nordisk

Médias

New Model Needed in Diabetes Care

Médias

Ryzodeg® Offers Improved glycaemic Control With Significantly Lower Rates of Hypoglycaemia Compared to biphasic insulin aspart 30 in Adults With Type 2 Diabetes[1]

Médias

Novo Nordisk se sitúa en el puesto 4 entre los Top 20 Science Employers del mundo

Médias

Novo Nordisk se classe au 4ème rang des 20 meilleurs employeurs au monde dans le domaine des sciences

Médias

Novo Nordisk Ranks 4th Among the World's Top 20 Science Employers

Médias

Investigational Ultra-long-acting Insulin Degludec Reduces Rates of Nocturnal Hypoglycaemia in Type 2 Diabetes Patients Versus Insulin Glargine